Back to full portfolio

Billion To One

Molecular diagnostics platform, using proprietary technology to develop diagnostic tests for pre-natal and oncology.
WEBSITE
Founder(s)
Oguzhan Atay, PhD and David Tsao, PhD
THEME(S)
Aligned care models
Emerging therapeutic platforms
SECTOR(S)
Healthcare
Investment Stage
Growth
Company Status
Private
Billion To OnePlay Icon

Perspectives

More about Billion To One

Perspectives

Investing in BillionToOne – Amplifying the power of molecular diagnostics

Read more

Investing in BillionToOne – Amplifying the power of molecular diagnostics

Read more
Perspectives

BillionToOne Announces Green Journal Publication that Underscores the Role of cell-free DNA NIPT for Fetal Red Blood Cell Antigen Genotyping

July 26, 2024
Read more

BillionToOne Announces Green Journal Publication that Underscores the Role of cell-free DNA NIPT for Fetal Red Blood Cell Antigen Genotyping

Read more
Perspectives

BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests

March 18, 2025
Read more

BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests

Read more
Billion to One
Perspectives

MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST

April 17, 2024
Read more
Billion to One
Billion to One

MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST

Read more
PR Newswire
Perspectives

BillionToOne Announces Medicare Coverage for Northstar Select

April 16, 2025
Read more
PR Newswire
PR Newswire

BillionToOne Announces Medicare Coverage for Northstar Select

Read more